Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2017 /
Temporary ovarian suppression with hormone analogue may preserve fertility during breast cancer chemotherapy

5th - 9th Dec 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.12.17
Views: 931

Dr Matteo Lambertini - Institut Jules Bordet, Brussels, Belgium

Dr Matteo Lambertini meets with ecancer at SABCS 2017 to discuss the safety and effects on fertility of temporary ovarian suppression during breast cancer treatment with gonadotrophin releasing hormone (GnRH) analogues.

Looking at data from 5 European trials, Dr Lambertini outlines the safety and lasting fertility of the total patient populations, half of whom received GRH alongside their cancer treatments.

With improved fertility and ovarian function, as well as equal safety and overall survival scores, Dr Lambertini recommends this as a treatment option for all young breast cancer patients concerned with their later ovarian function.

Watch the press conference for more.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation